{"id":"pqp","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Visual disturbances"}]},"_chembl":null,"_dailymed":{"setId":"6dba844a-db02-44f8-8593-ce497ed9406c","title":"PALYNZIQ (PEGVALIASE-PQPZ) INJECTION, SOLUTION [BIOMARIN PHARMACEUTICAL INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PQP belongs to the 4-aminoquinoline class of antimalarials and works by intercalating into parasite DNA and inhibiting essential enzymes required for DNA synthesis and repair. This mechanism is effective against multiple Plasmodium species and helps prevent both clinical malaria and transmission.","oneSentence":"PQP is a quinolone-based antimalarial that inhibits parasite DNA gyrase and topoisomerase II, disrupting DNA replication in Plasmodium species.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T06:22:33.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria prevention and treatment (Plasmodium falciparum and other species)"}]},"trialDetails":[{"nctId":"NCT05160363","phase":"PHASE1","title":"A Healthy Volunteer Safety Study of Pyronaridine Tetraphosphate Taken in Combination With Piperaquine Tetraphosphate","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2022-02-14","conditions":"Healthy","enrollment":37},{"nctId":"NCT03542149","phase":"PHASE1","title":"Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2018-04-23","conditions":"Malaria","enrollment":24},{"nctId":"NCT03208907","phase":"PHASE3","title":"DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil","status":"COMPLETED","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2018-07-05","conditions":"Malaria, Vivax, Therapeutics","enrollment":419},{"nctId":"NCT02909712","phase":"PHASE2","title":"Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2016-09","conditions":"Malaria, Pregnancy Malaria, Cardiotoxicity","enrollment":201},{"nctId":"NCT02802501","phase":"PHASE3","title":"Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-08","conditions":"Malaria, Vivax","enrollment":150},{"nctId":"NCT02431637","phase":"PHASE1","title":"Experimental Falciparum Transmission to Anopheles","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2015-04","conditions":"Malaria","enrollment":6},{"nctId":"NCT02914145","phase":"NA","title":"Mass Drug Administrations of DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2015-11","conditions":"Malaria","enrollment":240502},{"nctId":"NCT02184637","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-31","conditions":"Malaria, Vivax","enrollment":120},{"nctId":"NCT02568098","phase":"PHASE1","title":"Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-10","conditions":"Drug Combination, Pharmacokinetics, Healthy","enrollment":16},{"nctId":"NCT02083380","phase":"PHASE2, PHASE3","title":"Phase II Efficacy Study of Artefenomel & Piperaquine in Adults & Children With P. Falciparum Malaria.","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2014-07","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":448},{"nctId":"NCT00561899","phase":"PHASE2, PHASE3","title":"Comparison of Three Drug Combinations for Intermittent Treatment of Malaria in Children","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2007-08","conditions":"Malaria","enrollment":1295},{"nctId":"NCT01992900","phase":"PHASE2","title":"A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2013-11","conditions":"Malaria,Falciparum","enrollment":300},{"nctId":"NCT02387580","phase":"PHASE1","title":"Bioavailability Study of Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate (PQP) Tablets","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2015-04","conditions":"Malaria","enrollment":48},{"nctId":"NCT02461186","phase":"PHASE2, PHASE3","title":"Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar","status":"WITHDRAWN","sponsor":"University of Oxford","startDate":"2015-06","conditions":"Uncomplicated Falciparum Malaria, Artemisinin-resistant","enrollment":""},{"nctId":"NCT01958619","phase":"PHASE1","title":"Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2013-10","conditions":"Malaria","enrollment":55},{"nctId":"NCT01853475","phase":"PHASE1","title":"Healthy Volunteer Study of the Pharmacokinetics of Oral Piperaquine With OZ439 + TPGS Formulation in the Fasted State","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2013-04","conditions":"Malaria","enrollment":24},{"nctId":"NCT02083406","phase":"PHASE1","title":"Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2014-07","conditions":"Malaria","enrollment":22},{"nctId":"NCT01660022","phase":"PHASE1","title":"Safety Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 & Piperaquine to Healthy Subjects","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2012-09","conditions":"Healthy","enrollment":59},{"nctId":"NCT02199951","phase":"","title":"Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania","status":"UNKNOWN","sponsor":"INDEPTH Network","startDate":"2013-09","conditions":"Malaria","enrollment":10000},{"nctId":"NCT01552330","phase":"PHASE1","title":"Pharmacokinetic Study of Primaquine and Pyronaridine-Artesunate in Healthy Subjects","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-05","conditions":"Healthy","enrollment":17},{"nctId":"NCT01525511","phase":"PHASE1","title":"Pharmacokinetic Study of Primaquine and Dihydroartemisinin-Piperaquine in Healthy Subjects","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-06","conditions":"Healthy","enrollment":16},{"nctId":"NCT01222962","phase":"PHASE1","title":"Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2010-03","conditions":"Malaria, Falciparum","enrollment":37},{"nctId":"NCT01222949","phase":"PHASE1","title":"A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2010-02","conditions":"Malaria, Falciparum","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PQP 960 mg tablets"],"phase":"marketed","status":"active","brandName":"PQP","genericName":"PQP","companyName":"Medicines for Malaria Venture","companyId":"medicines-for-malaria-venture","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PQP is a quinolone-based antimalarial that inhibits parasite DNA gyrase and topoisomerase II, disrupting DNA replication in Plasmodium species. Used for Malaria (treatment and prevention).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}